Drug Type Monoclonal antibody |
Synonyms hrRNLS, human recombinant renalase (Bessor Pharma) |
Target |
Action modulators |
Mechanism RNLS modulators(renalase, FAD dependent amine oxidase modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Melanoma | Preclinical | United States | 13 Sep 2024 | |
| Pancreatic Cancer | Preclinical | United States | 13 Sep 2024 | |
| Pancreatitis | Preclinical | United States | 20 Sep 2016 |






